Kaleido Biosciences Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Kaleido Biosciences's estimated annual revenue is currently $16M per year.
- Kaleido Biosciences received $101.0M in venture funding in June 2018.
- Kaleido Biosciences's estimated revenue per employee is $164,588
- Kaleido Biosciences's total funding is $101M.
- Kaleido Biosciences has 97 Employees.
- Kaleido Biosciences grew their employee count by -29% last year.
- Kaleido Biosciences currently has 5 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Thermo Fisher S...||$2147.5M||55189||N/A||N/A|
|Advera Health A...||$2.4M||12||N/A||N/A|
|Olympus Life Sc...||$17.2M||76||10%||N/A|
|De Novo Softwar...||$3.6M||25||N/A||N/A|
|American Gene T...||$3.9M||30||N/A||N/A|
What Is Kaleido Biosciences?
Kaleido is a clinical-stage healthcare company leading the discovery and development of novel chemistries to drive functions of the microbiome organ to treat disease and improve human health. The company is advancing a robust pipeline of Microbiome Metabolic Therapies (MMTs) across a range of therapeutic areas, including rare genetic disorders. Kaleido's unique discovery and development model is redefining traditional R&D, enabling product candidates to advance rapidly into the clinic, dramatically reducing time and cost. Learn more at https://kaleido.com/.keywords:N/A
Number of Employees
Employee Growth %
|Yanjie Gu||Principal scientist/Associate Director|
|Jeffrey Cehelsky||Vice President Clinical Operations|
|Michael Bruce||Svp Project Portfolio Alliance Mgmt|
|Wendy Arnold||SVP, Human Resources|
|Kim Hocknell||Sr. Director, External Manufacturing|
|Stephen Sofen||SVP Techical Operations|
|Roberto Vincent||Clinical Project Manager|
|Yan Zheng||Sr Director, Biostatistics|
|Elisa Asanza||Director, Regulatory Affairs|
|Steven Fukuda||Sr. Clinical Project Manager|
Kaleido Biosciences News
Kaleido Biosciences Inc (NASDAQ:KLDO) was the target of a significant growth in short interest in the month of August. As of August 31st, there ...
Kaleido BioSciences, Inc. (NasdaqGS:KLDO) currently has a Value Composite score of 88. Similarly, the Value Composite Two (VC2) is ...
After completing its last trading session, Kaleido Biosciences, Inc. (KLDO) dropped by -0.1% – here is what that looked like (as of 2019-09-13): ...
Kaleido Biosciences Funding
Kaleido Biosciences Executive Hires
|2017-12-13||Alison Lawton||President & COO||Article|
|2018-01-04||Wendy Arnold||SVP HR||Article|
|2018-03-27||Stephen Sofen||VP Technical Operations||Article|
|2018-04-24||Joshua Brumm||Chief Financial Officer||Article|
|2018-12-04||Katharine Knobil||Chief Medical Officer and Head of Research & Development||Article|